Evidence map›Paper›PMID 25520876›Full record

ArticleAmerican journal of cancer research2014

Involvement of different mechanisms for the association of CAG repeat length polymorphism in androgen receptor gene with prostate cancer.

Xueying Mao, Jie Li, Xingxing Xu, Lara K Boyd, Weiyang He, Elzbieta Stankiewicz, Sakunthala C Kudahetti, Guangwen Cao, Daniel Berney, Guosheng Ren and 3 more

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Height, Obesity, and the Risk ofCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018
    Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Xueying MaoCentre for Molecular Oncology, Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London London, UK.
Jie LiDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University Chongqing, China.
Xingxing XuDepartment of Epidemiology, Second Military Medical University Shanghai, China.
Lara K BoydCentre for Molecular Oncology, Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London London, UK.
Weiyang HeDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University Chongqing, China.
Elzbieta StankiewiczCentre for Molecular Oncology, Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London London, UK.
Sakunthala C KudahettiCentre for Molecular Oncology, Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London London, UK.
Guangwen CaoDepartment of Epidemiology, Second Military Medical University Shanghai, China.
Daniel BerneyCentre for Molecular Oncology, Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London London, UK.
Guosheng RenMolecular Oncology and Epigenetics Laboratory, The First Affiliated Hospital, Chongqing Medical University of Chongqing China.
Xin GouDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University Chongqing, China.
Hongwei ZhangDepartment of Epidemiology, Second Military Medical University Shanghai, China.
Yong-Jie LuCentre for Molecular Oncology, Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London London, UK.
Queen Mary University of London · GBThe Affiliated Yongchuan Hospital of Chongqing Medical University · CNSecond Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While androgen and androgen receptor (AR) activity have been strongly implicated in prostate cancer development and therapy, the influence of the CAG repeat, which is found within the first exon of the AR gene, on prostate carcinogenesis is still unclear. We investigated the differences in the length of the CAG repeat between prostate cancer patients and controls in the Chinese population as well as between TMPRSS2:ERG fusion positive and negative samples. A general association between prostate cancer and either longer or shorter AR CAG repeat length was not observed in the Chinese population. However, our data suggest that certain CAG repeat lengths may increase or decrease prostate cancer risk. Shorter CAG repeat length was also not shown to be associated with a higher induction rate of TMPRSS2 and ERG proximity, an essential step for TMPRSS2:ERG fusion formation. However, samples with a CAG repeat of 17 were found more frequently in the TMPRSS2:ERG fusion positive than negative prostate cancer cases and mediated a higher rate of androgen-induced TMPRSS2 and ERG co-localisation than AR with longer (24) and shorter (15) CAG repeats. This suggests that 17 CAG repeats may be associated with TMPRSS2:ERG fusion positive prostate cancer, but may have a preventive role for prostate cancer in the Chinese population, which has a low TMPRSS2:ERG fusion frequency. This study suggests that different mechanisms for the association of CAG repeat length polymorphism and prostate cancer exist in different ethnic populations.

Indexed as

androgen receptor geneCAG repeatlength polymorphismprostate cancer

Identifiers

PMID25520876
PMCPMC4266720
OpenAlexW299890596

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.